Search Within

Nancy T Sklarin

Formats
  1. Journal Article (30)
  2. Meeting Abstract (24)
Groups
  1. Breast Medicine Service (54)
  2. Department of Medicine (54)
  3. Solid Tumor Oncology Division (54)
  4. Survivorship Research (40)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (36)
  6. Behavioral Sciences Service (24)

More Groups

People
  1. Clifford Hudis (38)
  2. Larry Norton (32)
  3. Andrew Seidman (30)
  4. Teresa Gilewski (24)
  5. Monica Fornier (20)
  6. Gabriella D'Andrea-Carlino (19)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2022 (1)
  4. 2021 (1)
  5. 2019 (1)
  6. 2018 (1)

More Years

Publications
  1. Journal of Clinical Oncology (19)
  2. Breast Cancer Research and Treatment (7)
  3. Cancer Research (4)
  4. Clinical Cancer Research (4)
  5. Seminars in Oncology (3)
  6. Annals of Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (20)
  2. American Association for Cancer Research (9)
  3. Springer (7)
  4. Elsevier Inc. (6)
  5. Lippincott Williams & Wilkins (3)
  6. Oxford University Press (3)

More Publishers

Results (54)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pathologic features and outcomes of pregnancy-associated breast cancer (PABC): A case control study
    Meeting Abstract

    Murphy, C.; Mallam, D.; Stein, S.; Patil, S.; Howard, J.; Sklarin, N. T.; Gemignani, M.; Hudis, C.; Seidman, A. D.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Correlative biomarkers in a phase II study of dasatinib (D) and weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)
    Meeting Abstract

    Morris, P. G.; Chang, J. C.; Abbruzzi, A.; Patil, S.; Modi, S.; Seidman, A. D.; Sklarin, N. T.; Norton, L.; Hudis, C.; Fornier, M. N.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • A phase I-II trial of dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)
    Meeting Abstract

    Morris, P. G.; Abbruzzi, A.; D'Andrea, G.; Gilewski, T.; Lake, D.; Bromberg, J.; Dang, C.; Dickler, M.; Modi, S.; Seidman, A. D.; more...
    Cancer Research (2010)

    Fulltext@MSK | Save
  • Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer
    Journal Article

    Drullinsky, P.; Sugarman, S. M.; Fornier, M. N.; D'Andrea, G.; Gilewski, T.; Lake, D.; Traina, T.; Wasserheit-Lieblich, C.; Sklarin, N.; Atieh-Graham, D.; more...
    Clinical Breast Cancer (2010)

    Fulltext@MSK | Save
  • Trastuzumab 6 mg/kg and 4 mg/kg can be infused safely over 30 minutes
    Meeting Abstract

    Chan, A. S.; Freeswick, S.; Sklarin, N. T.
    Cancer Research (2009)

    Fulltext@MSK | Save
  • The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Journal Article

    Dang, C.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Dickler, M.; Currie, V.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Bevacizumab 5mg/kg can be safely infused over 10 minutes
    Meeting Abstract

    Reidy, D. L.; Chung, K. Y.; Timoney, J. P.; Park, V.; Hollywood, E.; Sklarin, N.; Muller, R.; Saltz, L.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Bevacizumab 5 mg/kg can be infused safely over 10 minutes
    Journal Article

    Reidy, D. L.; Chung, K. Y.; Timoney, J. P.; Park, V. J.; Hollywood, E.; Sklarin, N. T.; Muller, R. J.; Saltz, L. B.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Updated cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C.; Smith, K.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Norton, L.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Mature cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C.; Smith, K.; Fornier, M.; Sugarman, S.; Troso, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; George, R.; more...
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save